Table 3

Outcome of patients with ND disease treated with full-dose or reduced-dose regimens

Any grade 3-4 AEs, %Discontinuation rate because of toxicity, %PFS, %OS, %
Standard dose therapies
    VMP4791350 at 2 y68 at 3 y
    RD51522748 at 2 y78 at 2 y
Lower dose therapies
    VMP57,655112-1746-50 at 3 y74-87 at 3 y
    Rd51351952 at 2 y88 at 2 y
  • AE indicates adverse event; PFS, progression-free survival; OS, overall survival; RD lenalidomide plus high-dose dexamethasone; and Rd, lenalidomide plus low-dose dexamethasone.